SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon

Kenechukwu Obumneme Samuel Nwosu(University of Geneva), Joseph Fokam(University of Buea), Franck Wanda, Lucien Mama(Ministry of Public Health), Erol Orel(University of Geneva), Nicolas Ray(University of Geneva), Jeanine Meke, Armel Tassegning, Désiré Takou(Centre International De Reference Chantal Biya), Eric Mimbe(Central Hospital of Yaoundé), Béat Stoll(University of Geneva), Josselin Guillebert(WWF Cameroon), Éric Comte(University of Geneva), Olivia Keiser(University of Geneva), Laura Ciaffi(Central Hospital of Yaoundé)
Nature Communications
October 6, 2021
Cited by 62Open Access
Full Text

Abstract

The extent of SARS-CoV-2 circulation in many African countries remains unclear, underlining the need for antibody sero-surveys to assess the cumulative attack rate. Here, we present the results of a cross-sectional sero-survey of a random sample of residents of a health district in Yaounde, Cameroon, conducted from October 14 to November 26, 2020. Among the 971 participants, the test-adjusted seroprevalence of anti-SARS-CoV-2 IgG antibodies was 29·2% (95% CI 24·3-34·1). This is about 322 times greater than the 0.09% nationwide attack rate implied by COVID-19 case counts at the time. Men, obese individuals and those living in large households were significantly more likely to be seropositive, and the majority (64·2% [58·7-69·4]) of seropositive individuals reported no symptoms. Despite the high seroprevalence, most of the population had not been infected with SARS-CoV-2, highlighting the importance of continued measures to control viral spread and quick vaccine deployment to protect the vulnerable.


Related Papers

No related papers found

Powered by citation graph analysis